Boston biotech re­cruits Sanofi’s US can­cer re­search chief; Syn­dax in-li­cens­es Al­ler­gan port­fo­lio

→Boston-based Sil­i­con Ther­a­peu­tics has re­cruit­ed Sanofi’s US can­cer R&D chief Christo­pher Win­ter to come over and run the R&D side of the busi­ness. Sil­i­con has ad­vanced new tech fo­cused on physics-based sim­u­la­tions, chem­istry and dis­ease bi­ol­o­gy. This is just the lat­est in a long line­up of phar­ma in­ves­ti­ga­tors mak­ing their way to the biotech world.

Syn­dax $SNDX CEO Brig­gs Mor­ri­son has in-li­censed a port­fo­lio of pre­clin­i­cal, oral small mol­e­cule in­hibitors of the in­ter­ac­tion of menin with the mixed lin­eage leukemia pro­tein from Vi­tae, a sub­sidiary of Al­ler­gan.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.